SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (15474)2/20/1998 11:32:00 AM
From: Andreas Helke  Read Replies (1) | Respond to of 32384
 
Entremed could be a good addition to a Ligand heavy biotech portfolio. If Entremeds anti angiogenesis cancer therapy really works that could be a major blow to Ligands and every one else cancer programs. Of course they are still in early stage preclinical research which allows Entremeds share price to fluctuate wildly.

Andreas



To: Henry Niman who wrote (15474)2/21/1998 7:57:00 AM
From: Henry Niman  Read Replies (1) | Respond to of 32384
 
Someone on the Yahoo board suggested that the enmd/lgnd post as a deliberate falsification. I asked where the original info came from and was told CNBC. However, I did not hear anything and was unable to confirm at the CNBC site.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News